Jan Peter Olofsson
Fondatore presso Redoxis AB
Posizioni attive di Jan Peter Olofsson
Società | Posizione | Inizio | Fine |
---|---|---|---|
Redoxis AB
Redoxis AB Medical SpecialtiesHealth Technology Redoxis AB focuses on preclinical drug development and validation in autoimmune diseases. The firm focuses on preclinical development of small molecules that target molecular pathways in the immunological responses associated with autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The company was founded by David Rikard Martinsson Holmdahl and Jan Peter Olofsson in 2007 and is headquartered in Gothenburg, Sweden. | Direttore/Membro del Consiglio | 01/01/2007 | - |
Fondatore | 01/01/2007 | - | |
Amministratore Delegato | 01/01/2007 | - | |
ProNoxis AB
ProNoxis AB Pharmaceuticals: MajorHealth Technology ProNoxis AB develops small-molecule drugs to treat chronic inflammation. The company was founded in 2009 and is headquartered in Lund, Sweden. | Amministratore Delegato | - | - |
Direttore/Membro del Consiglio | 28/12/2009 | - | |
Corporate Officer/Principal | 28/12/2009 | 26/07/2011 |
Storia della carriera di Jan Peter Olofsson
Precedenti posizioni note di Jan Peter Olofsson
Società | Posizione | Inizio | Fine |
---|---|---|---|
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Direttore/Membro del Consiglio | - | 31/12/2009 |
Corporate Officer/Principal | - | - | |
Arexis AB
Arexis AB Pharmaceuticals: MajorHealth Technology Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden. | Corporate Officer/Principal | - | - |
Formazione di Jan Peter Olofsson
University of Lund | Doctorate Degree |
University of Gothenburg | Masters Business Admin |
Statistiche
Distribuzione geografica
Svezia | 7 |
Posizioni
Director/Board Member | 3 |
Corporate Officer/Principal | 3 |
Chief Executive Officer | 2 |
Settori
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 4 |
---|---|
Redoxis AB
Redoxis AB Medical SpecialtiesHealth Technology Redoxis AB focuses on preclinical drug development and validation in autoimmune diseases. The firm focuses on preclinical development of small molecules that target molecular pathways in the immunological responses associated with autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The company was founded by David Rikard Martinsson Holmdahl and Jan Peter Olofsson in 2007 and is headquartered in Gothenburg, Sweden. | Health Technology |
ProNoxis AB
ProNoxis AB Pharmaceuticals: MajorHealth Technology ProNoxis AB develops small-molecule drugs to treat chronic inflammation. The company was founded in 2009 and is headquartered in Lund, Sweden. | Health Technology |
Arexis AB
Arexis AB Pharmaceuticals: MajorHealth Technology Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden. | Health Technology |
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Commercial Services |
- Borsa valori
- Insiders
- Jan Peter Olofsson
- Esperienza